HEMABATE SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

CARBOPROST (CARBOPROST TROMETHAMINE)

Inapatikana kutoka:

PFIZER CANADA ULC

ATC kanuni:

G02AD04

INN (Jina la Kimataifa):

CARBOPROST

Kipimo:

250MCG

Dawa fomu:

SOLUTION

Tungo:

CARBOPROST (CARBOPROST TROMETHAMINE) 250MCG

Njia ya uendeshaji:

INTRAMUSCULAR

Vitengo katika mfuko:

1ML

Dawa ya aina:

Prescription

Eneo la matibabu:

OXYTOCICS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0133100001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2003-09-16

Tabia za bidhaa

_ _
PRODUCT MONOGRAPH
HEMABATE
® STERILE SOLUTION
(carboprost tromethamine injection USP)
250 µg/mL
PROSTAGLANDIN
Pfizer Canada Inc.
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
DATE OF REVISION:
FEBRUARY 21, 2014
CONTROL NO. 170114
®
Pfizer Enterprises SARL
Pfizer Canada Inc, Licensee
Pfizer Canada Inc. 2014
_` _
_HEMABATE (carboprost tromethamine) Product Monograph _
_Page 2 of 23 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY OF PRODUCT INFORMATION
..................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II: SCIENTIFIC INFORMATION
................................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................14
DETAILED PHARMACOLOGY
...................................................................................